Researchers at the Colorado Blood Cancer Institute have devised a successful, long-term treatment for relapsing/remitting multiple sclerosis (RRMS). The treatment approach seeks to ‘reboot’ the patient’s immune system by effectively erasing it and then rebooting it using the patient’s own [autologous] stem cells. The treatment resulted in a disease reversal rate of 86% and halted progression rate of 91% in patients participating in the study. Study patients underwent immunosuppressive therapy for up to four weeks, after which autologous stem cells were re-infused to restore a healthy immune systems. Patients were then followed for up to five years.
In a newly published phase II clinical trial from the Asan Medical Center in Seoul, Korea, researchers observed full recovery from fistulas [abnormal connections between organs caused by the inflammation] in 75% of patients suffering from Crohn’s disease upon the injection of autologous [the patient’s own] stem cells. MSCs have the ability to regulate the patient’s immune system to reduce inflammation, resulting in the complete closure of the fistulas without recurrence.
Topics: large intestine, bank dental stem cells, Crohn's Disease, autologousstemcells, autoimmune disease, gastrointestinal disease, autoimmune attack, research, StemSave, mesenchymal stem cells, organs, stem cells, Fistulas
In a recently published study from the Queen Mary University of London, scientists discovered a connection between the length of cilia [hair-like projections for cell movement] on stem cells and their proclivity towards differentiating into fat cells. By restricting the elongation of stem cell cilia, the researchers were able to impede on the formation of new fat cells.
The New York-based startup Epibone intends to begin human testing on a procedure that will utilize stem cells to regenerate living bone tissue. The researchers, originally from Columbia University, will apply autologous [the patient’s own] stem cells to nanofiber scaffolding of the desired size and shape and direct the stem cells to differentiate into a physical and genetic replica of the patient’s own bone.
Topics: osteoporosis, limbs, Fingers, Jaw, Bone loss, Joints, Bone, Debilitating Diseases, Arthritis, Stemcells, Knee, hip, autologousstemcells, cartilage, grants, Mandibular bone, young stem cells, stemsaveblog
The Multiple Sclerosis Society of Canada has funded Canada’s first stem cell clinical trial to treat multiple sclerosis, conducted by researchers at the University of Ottawa. The trial, called MESCAMS [Mesenchymal Stem Cell Therapy for Canadian MS patients], will comprise MSC infusions to the central nervous system to utilize their ability to regulate autoimmune attacks and reduce inflammation in 40 MS patients.
Topics: ALS, Phase III, neural stem cells, multiple sclerosis, Brain, clinical trials, Debilitating Diseases, Stemcells, autologousstemcells, Amyotrophic lateral sclerosis, Neurodegenerative disease, stemsaveblog
Ophthalmologists James L Funderburgh, Ph.D. and Fatima Syed-Picard, Ph.D. from the University of Pittsburgh have devised a method for treating corneal blindness by utilizing dental pulp stem cells. The researchers harvested the stem cells from molars discarded during routine extraction and induced the cells to differentiate into keratocytes [corneal cells]. They then seeded the cells onto a nanofiber scaffold, allowing them to grow into fully developed, functional corneas capable of restoring eyesight.
In a new two year clinical trial conducted by the University of Miami, researchers will attempt to treat deep second degree burn victims with mesenchymal stem cells [MSCs] as a potential alternative to skin grafts. The team, led by Dr. Evangelos Badiavas, will first cover the wounds in protective dressing, and then inject the MSCs under the dressing and into the wounds to spur the regeneration of the inner and outer layers of skin.
Researchers from Okayama University have developed a method to treat the congenital heart defect known as hypoplastic left heart syndrome [HLHS] by utilizing a specialized cardiac stem cell. In a Phase I clinical trial conducted on children suffering from HLHS, the scientists concluded that, because the young stem cells in children are more abundant and self-renewing than those in adults, intracoronary injection of stem cells is a safe and feasible approach to treating the condition.
Topics: Heart Valve, Phase III, Heart, Heart Failure, Pediatric Congenital Heart Disease, clinical trials, Debilitating Diseases, Stemcells, hypoplastic left heart syndrome, Heart Attack, autologousstemcells, heart disease, stemsaveblog
In a recently published study from the Hallym University College of Medicine, researchers have applied mesenchymal stem cells [MSCs] to animal models afflicted with global cerebral ischemia [GCI] to successfully reduce the associated neuronal damage. When compared to those that received no treatment, animals that received MSCs displayed a significant decrease in cell death, inflammation to the brain, and disruption of the blood brain barrier.
According to a recently published study from the Brigham and Woman’s Hospital, mesenchymal stem cells [MSCs] have the ability to reverse type I diabetes by suppressing the auto-immune attack of islet cells. Although the MSCs cannot be directly injected into the pancreas, the researchers utilized the surface adhesion molecule HCELL to hone the stem cells in on the inflamed islets, allowing them to normalize blood sugar levels without the use of insulin.